Molecular Templates

moleculartemplates.com

Molecular Templates (MTEM) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary Engineered Toxin Body (ETB) platform. MTEM’s first immunotoxin, MT-3724, is in clinical development for non-Hodgkin’s lymphoma. Pipeline products for additional oncology targets are being advanced toward clinical development. For more information, please visit MTEM’s website at www.mtem.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE

AGC Biologics | June 03, 2020

news image

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...

Read More

INDUSTRIAL IMPACT

ABCELLERA AND ATLAS VENTURE COLLABORATE TO EMPOWER THE DEVELOPMENT OF IMPACTFUL MEDICINES FOR PATIENTS

AbCellera and Atlas Venture | August 04, 2022

news image

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...

Read More

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

news image

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More

INDUSTRIAL IMPACT

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

news image

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More
news image

NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE

AGC Biologics | June 03, 2020

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...

Read More
news image

INDUSTRIAL IMPACT

ABCELLERA AND ATLAS VENTURE COLLABORATE TO EMPOWER THE DEVELOPMENT OF IMPACTFUL MEDICINES FOR PATIENTS

AbCellera and Atlas Venture | August 04, 2022

AbCellera and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ proven track record in forming innovative biotechnology companies and AbCellera’s unique ability to quickly deliver lead drug candidates to bring transformational new medicines to patients faster. "Ab...

Read More
news image

TEVOGEN BIO PARTNERED WITH NEAL FLOMENBERG TO EVALUATE TEVOGEN' S PROPRIETARY ANTIGEN-SPECIFIC T-CELL TECHNOLOGY AS A TREATMENT FOR COVID-19

Tevogen Bio | August 11, 2020

Tevogen Bio believes that its investigational highly purified antigen-specific T cell therapy holds promise in the treatment of viral infections including COVID-19 and Influenza A. This collaboration aims to harness Tevogen's proprietary immunotherapy platform and Dr. Flomenberg's expertise in immunology, histocompatibility and pioneering work in the immunology of stem cell transplantation. Tevogen Bio announces a joint partnership with renowned bone-marrow transplant expert Neal Flomenb...

Read More
news image

INDUSTRIAL IMPACT

MEMED RAISES $93M TO ACCELERATE COMMERCIALIZATION OF ITS HOST IMMUNE-RESPONSE PRODUCT PORTFOLIO

MeMed | January 10, 2022

MeMed, a leader in host response technologies, announces a $93 million private financing round, bringing total funding in the Company to over $200 million, including support from the U.S. Department of Defense and EU Commission. Funds will be used to scale up manufacturing, accelerate commercialization and expand MeMed’s pioneering host immune response product portfolio. MeMed’s technology suite decodes the body’s immune response within minutes, providing p...

Read More